Replies to post #30555 on Lexaria Bioscience Corp (LEXX)

[AgentSmith]

I'm already getting the impression that identifying BTI by name in such PRs isn't going to be the "big hush-hush no-no" Altria had clearly made it.

[AgentSmith]

If Lexaria’s technology is proven to increase the delivery and effectiveness of antiviral drugs, the company can make its technology available to researchers worldwide to maximize drug effectiveness.

How would this work, I wonder... "At a price,"...? "For free,"...? Something in between...?

Also: If it turns-out DehydraTECH makes remdesivir - among other things - say, 10% more bioavailable... Would there be some sort of "ethical obligation" on behalf of Gilead to use it?

I can see something "fast acting" (etc.) with something like NSAIDs - there's already all that in the market. And with vitamins there are things like lower dosages, etc.

But with a "this could save your life" drug...? If a non-DT course of treatment requires, say, "5" total doses of remdesivir at one dose a day, and Lexaria can prove that a DT-enabled version would only require say "2"... Is there Gilead going to "have to" partner with Lexaria because the FDA for instance might argue that it is obligated to formulate a better version of the drug if one is clearly possibly to formulate?

('Cause... One alternative to me seem to be that Gilead says "pass" to Lexaria, but Lexaria just makes it public information that remdesivir "could be better, but isn't" - "because Gilead won't let us make it so." Another thought is that there might be pressure on Lexaria to make the DT process somehow more available "because it can augment life-saving treatments.")

Questions, questions, questions...